Development of novel hybrid nanoparticles (NPs) consisting of a magnetic core, useful as MRI contrast agent, and an organic shell responsible for the cell receptor targeting action:
-NPs synthesis, characterization and functionalization with biomolecules
-In vitro studies in cells (viability and internalization)
-In vivo studies on tumor bearing mice.
Drug-loaded nanoparticles can be used to target selective cancer cells resulting in the localization of the therapeutic activity, which should strongly reduce the typical side-effects usually encountered with conventional chemotherapeutics.
Nanotechnology has potential in HIV treatment by two approaches: 1) improving the pharmacokinetic properties of antiretroviral drugs, and 2) assisting drugs to cross the biological barriers (e.g., the blood brain barrier) to target the virus reservoirs.
Bioengineered nanoparticles can be developed to localize, monitor and quantify the early stages of inflammatory bowel diseases (IBDs), particularly Crohn disease and ulcerative colitis inflammatory diseases, and to treat aggressive inflammatory disorders including IBDs, rheumatoid arthritis, transplant rejection, edema, sepsis, and other inflammatory conditions.
- INNOVATIVE WAYS TO DELIVER NPS ALTERNATIVE TO THE TRADITIONAL INTRAVENOUS ROUTES OF ADMINISTRATION
In vivo investigation of topical, oral and intranasal administration as promising non-invasive delivery options especially for a regional and/or local effect, ameliorating the patient compliance, improving the pharmacokinetics of degradable peptides and proteins, and reducing the frequently.
Synthesis and application of Silver and TiO2NPs as alternative antibacterial agents to toxic parabens in cosmetics.